We are delighted to announce the launch of a clinical study aiming at securing the CE marking of our Artificial Pancreas, in association with the Cellnovo insulin pump and the Dexcom continuous glucose monitoring (CGM). The CE marking certifies that a device is safe for the users. A CE-marked device has the authorization to be […]Read more
As announced in January 31st news, results from the first set of clinical trial have been presented and explained last week during ATTD 2017. A short reminder: the clinical trial involved 9 investigation centers and 40 people, separated into 3 groups: sedentary: patients received meals whose glucid quantity was calculated in advance, did not […]Read more
Following remarks and questions we received this week, this news is going to describe the artificial pancreas system. The first “Diabeloop” artificial pancreas (close loop) aims at treating adult type 1 diabetic patients only (aged over 18 years old). A pediatric version will quickly follow but requires more tests. The system will be prescribed by […]Read more
By the end of August 2016, we ended a first set of clinical trials with Diabeloop artificial pancreas. Tested by 40 people during 72 hours in hospitalization condition, results are very conclusive! They will be presented and explained by Pr. Helene Hanaire and Dr. Sylvia Franc during two oral presentations at the ATTD in Paris, […]Read more
Since more than a year, Diabeloop team constantly increases. While the first software developer joined the company in May 2015, rapidly followed by a second one, the team is now composed of 7 software developers working full time on the project, 1 person in charge of the industrialization part, 2 people who focus on regulatory […]Read more
The website makes you discover the new Diabeloop identity and also offers more functionalities : news, newsletter…Read more
Diabeloop launches a new wave of clinical trials.
Diabeloop artificial pancreas will be tested during 72 hours on approximately 40 patients.